RSV Vaccines Available Across Canada: What You Need to Know This Fall
Respiratory syncytial virus (RSV), a common cause of cold-like symptoms, can lead to severe respiratory issues in infants and the elderly. This fall, several provinces in Canada are rolling out new RSV vaccines and treatments to help curb seasonal infections.
Canada has approved two vaccines for older adults, Arexvy and Abrysvo, and monoclonal antibody treatments for infants. The National Advisory Committee on Immunization (NACI) has recommended RSV vaccines for adults over 75 and for those 60 and older living in long-term care facilities. Pregnant women can also receive the Abrysvo vaccine to pass on immunity to newborns.
For infants, two monoclonal antibodies are available: palivizumab, an older option requiring monthly injections, and nirsevimab, a newer single-dose shot offering protection throughout the RSV season. Some provinces, like Quebec and Ontario, are already offering free shots for newborns and high-risk seniors, while others may require individuals to pay out of pocket.
Experts urge Canadians to check with their healthcare providers about RSV vaccine availability in their province. While costs can range from $230 for the Abrysvo vaccine to nearly $1,000 for the nirsevimab shot, the benefits of protecting vulnerable populations from serious RSV complications are clear.
As RSV vaccines become more accessible, they promise to significantly reduce hospitalizations and severe infections this season.